Department of Clinical Pharmacy
Faculty & Staff
,BCPS - Board Certified Pharmacotherapy Specialist
,FCCP - Fellow: American College of Clinical Pharmacy
,FASHP - Fellow: American Society of Health-System Pharmacists
,Pharmacy, Duquesne University
Dr. Slain, Pharm.D is currently an Associate Professor at West Virginia University. He received his Pharmacy degree and his Doctor of Pharmacy (Pharm.D.) degree from Duquesne University in Pittsburgh. He then completed a residency and fellowship in infectious diseases pharmacotherapy at the Medical College of Virginia in Richmond. Additionally, he has the distinction of being a Board Certified Pharmacotherapy Specialist (BCPS) with Added Qualifications in Infectious Diseases.
Dr. Slain is an anti-infective clinical specialist on the WVU Infectious Diseases Consult Service and in the outpatient Infectious Diseases Clinic. In addition, he teaches in several courses in the schools of Pharmacy, Medicine, and Graduate Nursing. He has received multiple teaching awards for his novel teaching approaches in the School of Pharmacy.
Dr. Slain serves as an international consultant to schools of pharmacy and hospitals in other countries. He has helped programs in their development of clinical pharmacy education, pharmacy residency training, and antibiotic stewardship. He was a 2013 recipient of a Fulbright Scholars grant, which funded a project in Chennai India. Dr. Slain serves as the School of Pharmacy’s Global Affairs Liaison.
Dr. Slain is active at the national level in several infectious diseases and pharmacy associations. Dr. Slain was selected as "Clinician of the Year" by The Society of Infectious Diseases Pharmacists (SIDP). He is WVU’s faculty liaison to two national associations that serve the needs of clinical pharmacy practitioners (The American Society of Health-System Pharmacist (ASHP) and The American College of Clinical Pharmacy (ACCP). He is the program director and principal mentor for the Infectious Diseases Pharmacotherapy Specialized Residency.
Dr. Slain’s research has been published in respected peer-reviewed journals. Dr. Slain speaks frequently at regional, national, and international meetings and conferences.
Guarascio AJ, Slain D. Review of the New Oral Tablet and Intravenous Dosage Forms of Posaconazole. Pharmacotherapy 2015; 35:208-19.
Turner RB, Smith CB, Martello JL, Slain D. The role of doxycycline in Clostridium difficile infection acquisition. Ann Pharmacother 2014; 48:772-6.
Dong H, Slain D, Cheng J, Ma W, Liang WF. Eighteen Cases of Liver Injury Following Ingestion of Polygonum multiflorum. Compliment Ther Med 2014;22:70-4.
Stitely M, Sweet M, Slain D, Alons L, Holls C, Hochberg C, Briggs F. Plasma and tissue cefazolin concentrations in obese patients undergoing cesarean delivery receiving two differing doses of pre-operative cefazolin. Surg Infections 2013;14:455-9
Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect 2013 Feb;14(1):73-156.
Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health-Syst Pharm 2013;70:195-283
Guarascio AJ, Slain D, Cumpston A. Tacrolimus dose modification in hematopoietic cell transplant recipients following a change in therapy from fluconazole to voriconazole. ISRN Transplantation 2013; 281-285
Ross A, Slain D, Cumpston A, Bryant A, Hamadani M, Craig MD. Evaluation of an alternative Posaconazole prophylaxis regimen in patients with hematologic malignancies receiving stress ulcer prophylaxis. Int J Antimicrob Agents 2012; 40:557-61.
Guarascio AJ, Slain D, McKnight R, Petros K, Parker J, Wilson A, Defazio CM, Sarwari AR. A matched-control evaluation of an antifungal bundle in the intensive care unit at a university teaching hospital. Int J Clin Pharm 2012;34(5).
Slain D, Sarwari AR, Petros KO, McKnight R, Sager R, Mullett CJ, Wilson A, Thomas JG, Moffett K, Palmer HC, Dedhia HV. Impact of a multimodal antimicrobial stewardship program on Pseudomonas aeruginosa susceptibility and antimicrobial use in the intensive care unit. Crit Care Res Pract 2011; (2011): Article ID 416426.
Amsden JR, Slain D. Antifungal Dosing in Obesity: A Review of the Literature. Curr Fungal Infect Rep2011;5:83-91.
Bryant AM, Slain D, Cumpston A, Craig M. A post marketing evaluation of posaconazole plasma concentrations in neutropenic patients with hematologic malignancy receiving posaconazole prophylaxis. Int J Antimicrob Agents 2011;37;266-9.
Gizzi L, Slain D, Hare J, Sager R, Briggs F, Palmer HC. An Assessment of a Safety Enhancement to the Hospital Medication Reconciliation Process for Elderly Patients. Am J Geriatr Pharmacother 2010;8:127-35.
Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: A focus on current and future antifungal treatment options. Pharmacotherapy 2007; 27: 1711-21.
Slain D, Amsden J.R., Khakoo R.A., Fisher M.A., Lalka D., Hobbs G.R. Effect of High-Dose Vitamin C on the Steady-State Pharmacokinetics of the Protease Inhibitor Indinavir in Healthy Volunteers.Pharmacotherapy 2005;25:165-70.
Slain D, Abate M, Hodges BM, Stamatakis MK, Wolak S. Evaluation of an interactive response system to promote active learning and skills development in the doctor of pharmacy curriculum. Am J Pharm Educ2004;68(5):Article 117.
Stamatakis MK, Schreiber JM, Slain D, Gunel E. Vancomycin administration during dialysis with low-flux polysulfone membranes: Traditional versus a supplemental dosage regimen. Am J Health-Sys Pharm2003;60:1564-8.
Slain D, Miller K, Khakoo RA, Fisher MA, Wierman T, Jozefczyk K. Infrequent Occurrence of Amphotericin B Lipid Complex (ABLC)-Associated Nephrotoxicity in Various Clinical Settings at a University Hospital.Clinical Therapeutics 2002; 24:1636-42.
Slain D, Casdorph D, McIntire T. Assessment Of An Antiretroviral Adherence Sensitivity Training Exercise In The Doctor Of Pharmacy Curriculum. Am J Pharm Educ 2002: 66: 277-80.
Sadler BM, Chittick GE, Polk RE, Slain D, Kerkering TM, Studenberg S, Lou Y, Moore KHP, Wooley J, Stein DS. Metabolic disposition and pharmacokinetics of [14C]-Amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered in a single, oral dose to healthy male subjects. J Clin Pharmacol 2001; 41: 386-96.
Slain D, Rogers RD, Chapman S, Cleary J. Intravenous hydroxypropyl-b-cyclodextrin formulation of itraconazole: Formulary focus. Ann Pharmacother 2001; 35: 720-9.
Slain D, Pakyz A, Israel D, Monroe SG, Polk RE. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 2000;20:898-907.
Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 1999;19 (3):306-23.
Slain D. Invasive fungal infections. In: Schwinghammer TL, Ed. Pharmacotherapy Casebook and Instructor’s Guide, 9th Edition. McGraw-Hill, New York, 2014.
Slain D. Infections in immunocompromised patients: A patient-focused approach. In: Schwinghammer TL, Ed. Pharmacotherapy Casebook and Instructor’s Guide, 9th Edition. McGraw-Hill, New York, 2014.
Slain D. Antifungal Agents: Clinical Scenario and Significance sections (chapter 35), In: Lemke TL, Williams DA, Eds. Foye’s Principles of Medicinal Chemistry, 7th Edition. Lippincott Williams & Wilkins, Philadelphia, 2012.
Slain D. Antiviral Agents and Protease Inhibitors: Clinical Scenario and Significance section (chapter 38), In: Lemke TL, Williams DA, Eds. Foye’s Principles of Medicinal Chemistry, 7th Edition. Lippincott Williams & Wilkins, Philadelphia, 2012.Bergman S, Slain D. Dermatophytosis. In: Schwinghammer TL, Ed. Pharmacotherapy Casebook and Instructor’s Guide, 7th Edition. McGraw-Hill, New York, 2007.
Slain D. Pneumonia [Chapter 75]. In: Helms RA, Quan DJ, Eds. Textbook of Therapeutics: Drug and Disease Management, 8th edition. Lippincott Williams & Wilkins, Philadelphia, 2006.
Hodges B, Slain D. Ventilator-Associated Pneumonia [Case 30]. In: Helms RA, Quan DJ, Eds. Textbook of Therapeutics: Drug and Disease Management, 8th edition. Lippincott Williams & Wilkins, Philadelphia, 2006.
Antimicrobial Stewardship: A Global Phenomenon. Visiting Scholar lecture. Mahidol University, Bangkok, Thailand, March 24, 2015.
Current Concept for Antimicrobial Prophylaxis in Surgery. Presented at the Advances in Pharmacotherapeutics and Pharmacy Practice Conference. Bangkok, Thailand, March 19, 2015.
Global Threat of Antibiotic-Resistant Bacteria: Implications for Brazilian Pharmacists. Encontro Paulista de Farmaceuticos XV. Sao Paulo, Brazil, January 20, 2015.
Antiretroviral Therapy Update. Presented at the Midyear Clinical Meeting of the American Society of Health-System Pharmacists (ASHP), Anaheim, December 7-11, 2014.
Treatment and prophylaxis of prosthetic joint infections: Update on new guidelines. Annual Meeting of The American College of Clinical Pharmacy (ACCP). Austin, TX, October 12-15, 2014.
Complex Pneumonia Case. In the Pharmacotherapy Prep & Recertification Course. Presented at the Annual Meeting of the American Society of Health-System Pharmacists (ASHP), Las Vegas, NV. May 31-Jun 3, 2014.
Antimicrobial Stewardship: A Global Phenomenon. 2014 Forbidden City International Pharmacist Forum. Beijing, China. May 16-19, 2014.
Antimicrobial Stewardship in the Health-System and Beyond. Annual Meeting of the American Pharmacist Association (APhA). Orlando, FL. March 28-31, 2014.
HIV Complex Cases. In the Pharmacotherapy Prep & Recertification Course. Presented at the Midyear Clinical Meeting of the American Society of Health-System Pharmacists (ASHP), Orlando, FL. December 7-8, 2013.
Antimicrobial Resistance and Overuse. Global Threat of Antibiotic Resistance: An Indian Initiative Symposia. Chennai, India, June 22, 2013.
Antimicrobial Stewardship Programs. Apollo Specialty Hospital. Chennai, India. June 18, 2013.
Treatment of Clostridium difficile Infection. Presented at the Summer Meeting of the American Society of Health-System Pharmacists (ASHP), Minneapolis, MN June 1-2, 2013.
HIV Complex Cases. In the Pharmacotherapy Prep Course. Presented at the Summer Meeting of the American Society of Health-System Pharmacists (ASHP), Minneapolis, MN June 1-2, 2013.
What’s new in infectious diseases pharmacotherapy? Annual Meeting of the South Carolina Society of Health-System Pharmacists. Charleston, SC, March 24-26.
Combination Therapy for Gram-Negative Infections. Presented at the 47th Midyear Clinical Meeting of the American Society of Health-System Pharmacists, Las Vegas, NV. Dec. 5, 2012.
HIV Complex Cases. In the Pharmacotherapy Prep Course. Presented at the Summer Meeting of the American Society of Health-System Pharmacists (ASHP), Baltimore , MD. June 6-7, 2012.
Treating Infections in Neutropenic Cancer Patients: Perspectives of an American Clinical Pharmacist. Symposia on Reasonable Clinical Application of Antimicrobials in Cancer Patients. Fudan Cancer Center, Shanghai, China. April 22, 2012.
Antifungal Therapies. Department of Infectious Diseases Noon Conference. 1st Affiliated Hospital of the Zhejiang School of Medicine. Hangzhou, China. April 19, 2012.
Antimicrobial stewardship programs: How good is the data? Presented at the 46th Midyear Clinical Meeting of the American Society of Health-System Pharmacists, New Orleans, LA. December 5, 2011.
Antibiotic Stewardship: An essential part of an infection control program. Three Rivers Association For Professionals in Infection Control (TRAPIC) Annual Meeting, Pittsburgh, PA October 14, 2011.
Anti-influenza Agents: Current and Future. Presented at the 45th Midyear Clinical Meeting of the American Society of Health-System Pharmacists, Anaheim, CA. December 6, 2010.
Clinical Practice Guidelines for the Management of Candidiasis. Presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Boston, MA. September 11, 2010.
Preparing for faculty positions: Insights from the Ivory Tower. Presented at the 44th Midyear Clinical Meeting of the American Society of Health-System Pharmacists, Las Vegas, NV. December 6, 2009.
Oral Vancomycin Formulations: An Infectious Diseases Pharmacist Perspective. Meeting of The Food and Drug Administration (FDA) Advisory Committee for Pharmaceutical Science and Clinical Pharmacology (ACPS-CP). Silver Spring, MD. August 4, 2009.
Healthcare-Associated Infections: Implications for Prudent Empiric Antibiotic Therapy. 43rd Annual American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting. Orlando, FL. December 8, 2008.
Infectious Diseases Residencies: A Preceptor Development Forum. Annual Meeting of the Society of Infectious Diseases Pharmacists (SIDP). Washington, D.C. October 24, 2008.
An Update on HIV Therapeutics for Pharmacists. Virginia Society of Health-System Pharmacists (VSHP) Annual Meeting, April 14-15, 2007, Wintergreen Resort, VA.
Treatment Of Fungal Pathogens In The Immunocompromised Patient. 16th Annual Conference of the National Home Infusion Association. Savannah, GA. February 26- March 1, 2007
Drugs vs. Bugs: A Concise Review of Key Issues in Anti-Infective Therapeutics. 41st Annual American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting. Anaheim, CA. December 9, 2006.
Empiric Therapy Decisions for Serious Infections: A Consideration of Appropriate Therapy. Pharmacotherapy Grand Rounds. University of Tennessee, Memphis, TN November 16, 2006
Safeguards for Serious Infections: A Consideration of Appropriate Empiric Antibiotic Therapy. Virginia Society of Health-System Pharmacists Meeting, Region IV. Richmond, VA. October 27, 2005.
A Seasoned Look at Newer Antifungals: Truly Advantageous or is Redundazole Here? Annual Meeting of the American College of Clinical Pharmacy. San Francisco, October 23-26, 2005
New Anti-Infectives and the Treatment of Resistant Organisms. 14th Annual Meeting of the National Home Infusion Association. New Orleans, LA. February 13, 2005.
Clinical Management of Fungal Infections. 14th Annual Meeting of the National Home Infusion Association. New Orleans, LA. February 13, 2005.
Linezolid vs.Vancomycin for the Treatment of Nosocomial or Ventilator-Associated Pneumonia. Significant Paper Session. Annual Meeting of the American College of Clinical Pharmacy. Dallas, TX. October 24-27, 2004.
New Antifungal Formulations. 38th Annual American Society of Health-System Pharmacists Midyear Clinical Meeting. New Orleans, LA. December 9, 2003
Teaching Interests and Courses Taught
PHAR 730 Pharmacotherapeutics III, Coordinator and Instructor
PHAR 739 Therapeutic Patient Monitoring, Instructor
PHAR 760 Acute Care Clinical Rotation-Infectious Diseases, Clinical Preceptor
PHAR 735 Pharmaceutical Care Lab-5, Instructor
PCOL 760 Medical Pharmacology – WVU Medical School, Instructor
NURS 391 Advanced Pharmacology for Nurse Practitioner Program, Instructor
Dr. Slain’s clinical practice sites at WVU include the Infectious Diseases Consult Service and the outpatient Infectious Diseases clinic. He is a member of WVU Hospitals Antibiotic Committee of the Pharmacy and Therapeutics Committee. He is a key member in the institution’s antibiotic stewardship program.
Research and Scholarship Interests
Global Pharmacy Practice
Anti-infective drug interactions
Respiratory tract infections
Antimicrobial use outcomes